Perioperative aspirin management after POISE-2: Some answers, but questions remain

Neal Stuart Gerstein, Michael Christopher Carey, Joaquin Cigarroa, Peter Schulman

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Aspirin constitutes important uninterrupted lifelong therapy for many patients with cardiovascular (CV) disease or significant (CV) risk factors. However, whether aspirin should be continued or withheld in patients undergoing noncardiac surgery is a common clinical conundrum that balances the potential of aspirin for decreasing thrombotic risk with its possibility for increasing perioperative blood loss. In this focused review, we describe the role of aspirin in treating and preventing cardiovascular disease, summarize the most important literature on the perioperative use of aspirin (including the recently published PeriOperative ISchemic Evaluation [POISE]-2 trial), and offer current recommendations for managing aspirin during the perioperative period. POISE-2 suggests that aspirin administration during the perioperative period does not change the risk of a cardiovascular event and may result in increased bleeding. However, these findings are tempered by a number of methodological issues related to the study. On the basis of currently available literature, including POISE-2, aspirin should not be administered to patients undergoing surgery unless there is a definitive guideline-based primary or secondary prevention indication. Aside from closed-space procedures, intramedullary spine surgery, or possibly prostate surgery, moderate-risk patients taking lifelong aspirin for a guideline-based primary or secondary indication may warrant continuation of their aspirin throughout the perioperative period.

Original languageEnglish (US)
Pages (from-to)570-575
Number of pages6
JournalAnesthesia and Analgesia
Volume120
Issue number3
DOIs
StatePublished - Mar 4 2015

Fingerprint

Aspirin
Perioperative Period
Cardiovascular Diseases
Guidelines
Primary Prevention
Risk-Taking
Secondary Prevention
Prostate
Spine
Hemorrhage

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Medicine(all)

Cite this

Perioperative aspirin management after POISE-2 : Some answers, but questions remain. / Gerstein, Neal Stuart; Carey, Michael Christopher; Cigarroa, Joaquin; Schulman, Peter.

In: Anesthesia and Analgesia, Vol. 120, No. 3, 04.03.2015, p. 570-575.

Research output: Contribution to journalArticle

Gerstein, Neal Stuart ; Carey, Michael Christopher ; Cigarroa, Joaquin ; Schulman, Peter. / Perioperative aspirin management after POISE-2 : Some answers, but questions remain. In: Anesthesia and Analgesia. 2015 ; Vol. 120, No. 3. pp. 570-575.
@article{7f9276b1bea84ce59a299fc97dfc738e,
title = "Perioperative aspirin management after POISE-2: Some answers, but questions remain",
abstract = "Aspirin constitutes important uninterrupted lifelong therapy for many patients with cardiovascular (CV) disease or significant (CV) risk factors. However, whether aspirin should be continued or withheld in patients undergoing noncardiac surgery is a common clinical conundrum that balances the potential of aspirin for decreasing thrombotic risk with its possibility for increasing perioperative blood loss. In this focused review, we describe the role of aspirin in treating and preventing cardiovascular disease, summarize the most important literature on the perioperative use of aspirin (including the recently published PeriOperative ISchemic Evaluation [POISE]-2 trial), and offer current recommendations for managing aspirin during the perioperative period. POISE-2 suggests that aspirin administration during the perioperative period does not change the risk of a cardiovascular event and may result in increased bleeding. However, these findings are tempered by a number of methodological issues related to the study. On the basis of currently available literature, including POISE-2, aspirin should not be administered to patients undergoing surgery unless there is a definitive guideline-based primary or secondary prevention indication. Aside from closed-space procedures, intramedullary spine surgery, or possibly prostate surgery, moderate-risk patients taking lifelong aspirin for a guideline-based primary or secondary indication may warrant continuation of their aspirin throughout the perioperative period.",
author = "Gerstein, {Neal Stuart} and Carey, {Michael Christopher} and Joaquin Cigarroa and Peter Schulman",
year = "2015",
month = "3",
day = "4",
doi = "10.1213/ANE.0000000000000589",
language = "English (US)",
volume = "120",
pages = "570--575",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Perioperative aspirin management after POISE-2

T2 - Some answers, but questions remain

AU - Gerstein, Neal Stuart

AU - Carey, Michael Christopher

AU - Cigarroa, Joaquin

AU - Schulman, Peter

PY - 2015/3/4

Y1 - 2015/3/4

N2 - Aspirin constitutes important uninterrupted lifelong therapy for many patients with cardiovascular (CV) disease or significant (CV) risk factors. However, whether aspirin should be continued or withheld in patients undergoing noncardiac surgery is a common clinical conundrum that balances the potential of aspirin for decreasing thrombotic risk with its possibility for increasing perioperative blood loss. In this focused review, we describe the role of aspirin in treating and preventing cardiovascular disease, summarize the most important literature on the perioperative use of aspirin (including the recently published PeriOperative ISchemic Evaluation [POISE]-2 trial), and offer current recommendations for managing aspirin during the perioperative period. POISE-2 suggests that aspirin administration during the perioperative period does not change the risk of a cardiovascular event and may result in increased bleeding. However, these findings are tempered by a number of methodological issues related to the study. On the basis of currently available literature, including POISE-2, aspirin should not be administered to patients undergoing surgery unless there is a definitive guideline-based primary or secondary prevention indication. Aside from closed-space procedures, intramedullary spine surgery, or possibly prostate surgery, moderate-risk patients taking lifelong aspirin for a guideline-based primary or secondary indication may warrant continuation of their aspirin throughout the perioperative period.

AB - Aspirin constitutes important uninterrupted lifelong therapy for many patients with cardiovascular (CV) disease or significant (CV) risk factors. However, whether aspirin should be continued or withheld in patients undergoing noncardiac surgery is a common clinical conundrum that balances the potential of aspirin for decreasing thrombotic risk with its possibility for increasing perioperative blood loss. In this focused review, we describe the role of aspirin in treating and preventing cardiovascular disease, summarize the most important literature on the perioperative use of aspirin (including the recently published PeriOperative ISchemic Evaluation [POISE]-2 trial), and offer current recommendations for managing aspirin during the perioperative period. POISE-2 suggests that aspirin administration during the perioperative period does not change the risk of a cardiovascular event and may result in increased bleeding. However, these findings are tempered by a number of methodological issues related to the study. On the basis of currently available literature, including POISE-2, aspirin should not be administered to patients undergoing surgery unless there is a definitive guideline-based primary or secondary prevention indication. Aside from closed-space procedures, intramedullary spine surgery, or possibly prostate surgery, moderate-risk patients taking lifelong aspirin for a guideline-based primary or secondary indication may warrant continuation of their aspirin throughout the perioperative period.

UR - http://www.scopus.com/inward/record.url?scp=84927680004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927680004&partnerID=8YFLogxK

U2 - 10.1213/ANE.0000000000000589

DO - 10.1213/ANE.0000000000000589

M3 - Article

C2 - 25695574

AN - SCOPUS:84927680004

VL - 120

SP - 570

EP - 575

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 3

ER -